245 related articles for article (PubMed ID: 35304420)
1. NeoScore Integrates Characteristics of the Neoantigen:MHC Class I Interaction and Expression to Accurately Prioritize Immunogenic Neoantigens.
Borden ES; Ghafoor S; Buetow KH; LaFleur BJ; Wilson MA; Hastings KT
J Immunol; 2022 Apr; 208(7):1813-1827. PubMed ID: 35304420
[TBL] [Abstract][Full Text] [Related]
2. Virus-like particle-mediated delivery of structure-selected neoantigens demonstrates immunogenicity and antitumoral activity in mice.
Barajas A; Amengual-Rigo P; Pons-Grífols A; Ortiz R; Gracia Carmona O; Urrea V; de la Iglesia N; Blanco-Heredia J; Anjos-Souza C; Varela I; Trinité B; Tarrés-Freixas F; Rovirosa C; Lepore R; Vázquez M; de Mattos-Arruda L; Valencia A; Clotet B; Aguilar-Gurrieri C; Guallar V; Carrillo J; Blanco J
J Transl Med; 2024 Jan; 22(1):14. PubMed ID: 38172991
[TBL] [Abstract][Full Text] [Related]
3. Cancer Neoantigens: Challenges and Future Directions for Prediction, Prioritization, and Validation.
Borden ES; Buetow KH; Wilson MA; Hastings KT
Front Oncol; 2022; 12():836821. PubMed ID: 35311072
[TBL] [Abstract][Full Text] [Related]
4. Challenges targeting cancer neoantigens in 2021: a systematic literature review.
Chen I; Chen MY; Goedegebuure SP; Gillanders WE
Expert Rev Vaccines; 2021 Jul; 20(7):827-837. PubMed ID: 34047245
[No Abstract] [Full Text] [Related]
5. pTuneos: prioritizing tumor neoantigens from next-generation sequencing data.
Zhou C; Wei Z; Zhang Z; Zhang B; Zhu C; Chen K; Chuai G; Qu S; Xie L; Gao Y; Liu Q
Genome Med; 2019 Oct; 11(1):67. PubMed ID: 31666118
[TBL] [Abstract][Full Text] [Related]
6. Machine learning methods and harmonized datasets improve immunogenic neoantigen prediction.
Müller M; Huber F; Arnaud M; Kraemer AI; Altimiras ER; Michaux J; Taillandier-Coindard M; Chiffelle J; Murgues B; Gehret T; Auger A; Stevenson BJ; Coukos G; Harari A; Bassani-Sternberg M
Immunity; 2023 Nov; 56(11):2650-2663.e6. PubMed ID: 37816353
[TBL] [Abstract][Full Text] [Related]
7. Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy.
Bai P; Li Y; Zhou Q; Xia J; Wei PC; Deng H; Wu M; Chan SK; Kappler JW; Zhou Y; Tran E; Marrack P; Yin L
Oncoimmunology; 2021 Jan; 10(1):1868130. PubMed ID: 33537173
[TBL] [Abstract][Full Text] [Related]
8. Untranslated regions (UTRs) are a potential novel source of neoantigens for personalised immunotherapy.
Sng CCT; Kallor AA; Simpson BS; Bedran G; Alfaro J; Litchfield K
Front Immunol; 2024; 15():1347542. PubMed ID: 38558815
[TBL] [Abstract][Full Text] [Related]
9. Neoantigen Dissimilarity to the Self-Proteome Predicts Immunogenicity and Response to Immune Checkpoint Blockade.
Richman LP; Vonderheide RH; Rech AJ
Cell Syst; 2019 Oct; 9(4):375-382.e4. PubMed ID: 31606370
[TBL] [Abstract][Full Text] [Related]
10. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
[TBL] [Abstract][Full Text] [Related]
11. Neoantigen vaccine: an emerging tumor immunotherapy.
Peng M; Mo Y; Wang Y; Wu P; Zhang Y; Xiong F; Guo C; Wu X; Li Y; Li X; Li G; Xiong W; Zeng Z
Mol Cancer; 2019 Aug; 18(1):128. PubMed ID: 31443694
[TBL] [Abstract][Full Text] [Related]
12. Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes.
Lu T; Wang S; Xu L; Zhou Q; Singla N; Gao J; Manna S; Pop L; Xie Z; Chen M; Luke JJ; Brugarolas J; Hannan R; Wang T
Sci Immunol; 2020 Feb; 5(44):. PubMed ID: 32086382
[TBL] [Abstract][Full Text] [Related]
13. TruNeo: an integrated pipeline improves personalized true tumor neoantigen identification.
Tang Y; Wang Y; Wang J; Li M; Peng L; Wei G; Zhang Y; Li J; Gao Z
BMC Bioinformatics; 2020 Nov; 21(1):532. PubMed ID: 33208106
[TBL] [Abstract][Full Text] [Related]
14. Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy.
Richard G; Princiotta MF; Bridon D; Martin WD; Steinberg GD; De Groot AS
Expert Rev Vaccines; 2022 Feb; 21(2):173-184. PubMed ID: 34882038
[TBL] [Abstract][Full Text] [Related]
15. Getting personal in metastatic melanoma: neoantigen-based vaccines as a new therapeutic strategy.
D'Alise AM; Scarselli E
Curr Opin Oncol; 2023 Mar; 35(2):94-99. PubMed ID: 36721894
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive mutanome analysis of Lewis lung cancer reveals immunogenic neoantigens for therapeutic vaccines.
Chen T; Hu R; Wan Y; Sun F; Wang Z; Yue J; Chen J; Han G; Wei G; Dong Z
Biochem Biophys Res Commun; 2020 May; 525(3):607-613. PubMed ID: 32115148
[TBL] [Abstract][Full Text] [Related]
17. Gene fusion neoantigens: Emerging targets for cancer immunotherapy.
Wang Y; Shi T; Song X; Liu B; Wei J
Cancer Lett; 2021 May; 506():45-54. PubMed ID: 33675984
[TBL] [Abstract][Full Text] [Related]
18. GNIFdb: a neoantigen intrinsic feature database for glioma.
Li W; Sun T; Li M; He Y; Li L; Wang L; Wang H; Li J; Wen H; Liu Y; Chen Y; Fan Y; Xin B; Zhang J
Database (Oxford); 2022 Feb; 2022():. PubMed ID: 35150127
[TBL] [Abstract][Full Text] [Related]
19. Splicing neoantigen discovery with SNAF reveals shared targets for cancer immunotherapy.
Li G; Mahajan S; Ma S; Jeffery ED; Zhang X; Bhattacharjee A; Venkatasubramanian M; Weirauch MT; Miraldi ER; Grimes HL; Sheynkman GM; Tilburgs T; Salomonis N
Sci Transl Med; 2024 Jan; 16(730):eade2886. PubMed ID: 38232136
[TBL] [Abstract][Full Text] [Related]
20. The role of neoantigens in tumor immunotherapy.
Shang S; Zhao Y; Qian K; Qin Y; Zhang X; Li T; Shan L; Wei M; Xi J; Tang B
Biomed Pharmacother; 2022 Jul; 151():113118. PubMed ID: 35623169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]